IVDR 2025
Don't miss the latest updates
Year: December 12, 2023
After different delays and not without concerns, the implementation of IVDR, the new regulatory framework for in-vitro diagnostic in the EU, has now started. Molecular testing in oncology is likely to be one of the areas in which this legislation will have a bigger impact, with questions and concerns having been raised by all the stakeholders involved in biomarker testing. However, IVDR is here to stay, and laboratories are facing a transition period in which they will need to adapt to this new reality.
Watch the session
"CE-IVDR: Where are we now in molecular testing?"
The implementation of the new CE-In Vitro Diagnostics Regulation (IVDR) involves challenges faced by labs that are working within the diagnostic environment. This event provided an overview of how IVDR implementation is progressing in different countries, and which are the most relevant challenges from a molecular pathology point of view. Five guest speakers from France, Spain, Italy, and the UK with experience in the field will share their point of view and discuss the current situation and future perspectives.
Download the report
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network ®
